CONTENTS

Section 1: Basic Sciences

Section Editor: Bhagirath Raghuraman

1. Biomarkers for the Identification of Cardiac Fibroblast and Myofibroblast Cells 1
2. Advances in the Diagnosis and Treatment of Transthyretin Amyloidosis with Cardiac Involvement 2
3. Anti-apoptosis in Nonmyocytes and Pro-autophagy in Cardiomyocytes: Two Strategies against Postinfarction Heart Failure through Regulation of Cell Death/Degeneration 4
4. The Long Non-coding Road to Endogenous Cardiac Regeneration 6
5. Role of Cytokines and Inflammation in Heart Function During Health and Disease 7
6. Structural and Functional Abnormalities in Iron-depleted Heart 9
7. Metabolic Remodelling in Heart Failure 10
8. The Relevance of microRNA in Post-infarction Left Ventricular Remodelling and Heart Failure 12
9. Mitochondrial Membrane Transporters and Metabolic Switch in Heart Failure 14
10. Right Ventricular Mechanical Pattern in Health and Disease: Beyond Longitudinal Shortening 16

Section 2: Heart Failure Clinics

Section Editor: Sandeep Seth

1. Introducing Nurse-led Heart Failure Clinics in Swedish Primary Care Settings 18
2. Nurse-led Heart Failure Clinics are Associated with Reduced Mortality but not Heart Failure Hospitalization 19
3. An Outpatient Heart Failure Clinic Reduces 30-day Readmission and Mortality Rates for Discharged Patients: Process and Preliminary Outcomes 20

Section 3: Registries

Section Editor: Hari Krishnan

1. In-hospital and Three-year Outcomes of Heart Failure Patients in South India: The Trivandrum Heart Failure Registry 21
2. Target Doses of Heart Failure Medical Therapy and Blood Pressure: Insights from the CHAMP-HF Registry 22
3. Medical Therapy for Heart Failure with Reduced Ejection Fraction: The CHAMP-HF Registry 24
4. Prevalence, Risk Factors, and Significance of Iron Deficiency and Anemia in Nonischemic Heart Failure Patients with Reduced Ejection Fraction from a Himachal Pradesh Heart Failure Registry 25
5. Association between Process Performance Measures and 1-year Mortality among Patients with Incident Heart Failure: A Danish Nationwide Study 27
6. Machine Learning Methods Improve Prognostication, Identify Clinically Distinct Phenotypes, and Detect Heterogeneity in Response to Therapy in a Large Cohort of Heart Failure Patients 28
7. Incidence of Hospital-acquired Hyponatremia by the Dose and Type of Diuretics among Patients with Acute Heart Failure and its Association with Long-term Outcomes 29
8. Early Ambulation among Hospitalized Heart Failure Patients is Associated with Reduced Length of Stay and 30-day Readmissions 31
9. Incidence, Predictors, and Outcome Associations of Dyskalemia in Heart Failure with Preserved, Mid-range, and Reduced Ejection Fraction 32
10. Beta-blockers and 1-year Postdischarge Mortality for Heart Failure and Reduced Ejection Fraction and Slow Discharge Heart Rate 34

Section 4: Biomarkers

Section Editor: Uday Jadhav

1. Cardiac Biomarkers in the Emergency Department: The Role of Soluble ST2 (sST2) in Acute Heart Failure and Acute Coronary Syndrome—There is Meat on the Bone 36
2. Soluble ST2—A New Biomarker in Heart Failure 37
3. Cardiovascular Biomarkers in Patients with Acute Decompensated Heart Failure Randomized to Sacubitril-valsartan or Enalapril in the PIONEER-HF Trial 39

4. Urinary Sodium Profiling in Chronic Heart Failure to Detect Development of Acute Decompensated Heart Failure 40
5. Utility of Cardiac Biomarkers in the Setting of Kidney Disease 42
6. Temporal Patterns of 14 Blood Biomarker Candidates of Cardiac Remodeling in Relation to Prognosis of Patients with Chronic Heart Failure—The Bio-SHiFT Study 43
7. Cardiovascular Biomarkers and Heart Failure Risk in Patients with Stable Atherothrombotic Disease: A Nested Biomarker Study from TRA 2°P-TIMI 50 45

Section 5: Imaging in Heart Failure in 2018

Section Editors: Jagdish Chander Mohan, Madhu Shukla, Vishwas Mohan

1. Advances in Imaging and Heart Failure: Where are We Heading? 47

Section 6: Acute Heart Failure

Section Editors: K Venugopal, Vijay K Chopra

1. The Effect of Door-to-diuretic Time on Clinical Outcomes in Patients with Acute Heart Failure 56
2. Frequency of Transition from Stage A to Stage B Heart Failure after Initiating Potentially Cardiotoxic Chemotherapy 57
3. Randomized Evaluation of Heart Failure with Preserved Ejection Fraction Patients with Acute Heart Failure and Dopamine: The ROPA-DOP Trial 59
4. Sudden Death in Heart Failure with Preserved Ejection Fraction and Beyond: An Elusive Target 60
5. Angiotensin–Neprilysin Inhibition in Acute Decompensated Heart failure 62
6. Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease 63
7. Influenza Vaccine in Heart Failure 65
8. Bio-adrenomedullin as a Marker of Congestion in Patients with New-onset and Worsening Heart Failure 66
9. Long-term Safety of Intravenous Cardiovascular Agents in Acute Heart Failure: Results from the European Society of Cardiology Heart Failure Long-term Registry 68
10. Outcomes Associated with a Strategy of Adjuvant Metolazone or High-dose Loop Diuretics in Acute Decompensated Heart Failure: A Propensity Analysis 69

Section 7: Chronic Heart Failure

Section Editors: Abraham Oomman, Vijay K Chopra

1. Lower Hospitalization and Healthcare Costs with Sacubitril/Valsartan versus Angiotensin-converting Enzyme Inhibitor or Angiotensin-receptor Blocker in a Retrospective Analysis of Patients with Heart Failure 71
2. Effects of Sacubitril/Valsartan on Physical and Social Activity Limitations in Patients with Heart Failure: A Secondary Analysis of the PARADIGM-HF Trial 73
3. Renal Effects and Associated Outcomes during Angiotensin-neprilysin Inhibition in Heart Failure 75
4. Sacubitril/Valsartan Reduces Ventricular Arrhythmias in Parallel with Left Ventricular Reverse Remodeling in Heart Failure with Reduced Ejection Fraction 77
5. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes 79
6. Comparison of the Effects of Glucagon-like Peptide Receptor Agonists and Sodium-glucose Cotransporter-2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis of Cardiovascular Outcomes Trials 81
7. Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics 83
8. SGLT-2 Inhibitors for Primary and Secondary Prevention of Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Systematic Review and Meta-analysis of Cardiovascular Outcome Trials 84
9. Comparative Effectiveness of Canagliflozin, SGLT-2 Inhibitors and Non-SGLT-2 Inhibitors on the Risk of Hospitalization for Heart Failure and Amputation in Patients with Type 2 Diabetes Mellitus: A Real-world Meta-analysis of 4 Observational Databases (OBSERVE-4D) 87

Section 8: Electrophysiology, Pacing and Ablation

Section Editor: Balbir Singh

1. Outcome of Cardiac Sarcoidosis Presenting with High-grade Atrioventricular Block 89
2. Catheter Ablation for Atrial Fibrillation with Heart Failure 90
3. Permanent His-bundle Pacing for Cardiac Resynchronization Therapy in Patients with Heart Failure and Right Bundle Branch Block 91
4. Effect of Interventricular Electrical Delay on Atrioventricular Optimization for Cardiac Resynchronization Therapy 93

5. Electrocardiographic Features Differentiating Arrhythmogenic Right Ventricular Cardiomyopathy from an Athlete's Heart 94

6. Outcomes of Catheter Ablation of Ventricular Tachycardia Based on Etiology in Nonischemic Heart Disease: An International Ventricular Tachycardia Ablation Center Collaborative Study 96

7. Risk Models for Prediction of Implantable Cardioverter-defibrillator Benefit: Insights from the DANISH Trial 97

8. Ventricular Arrhythmias and Sudden Cardiac Arrest in Takotsubo Cardiomyopathy: Incidence, Predictive Factors, and Clinical Implications 98

Section 9: Left Ventricular Assist Device and Transplant

Section Editor: Thirugnanasambandan Sunder

1. Predicted Heart Mass is the Optimal Metric for Size Match in Heart Transplantation 100

2. Donor Predicted Heart Mass as Predictor of Primary Graft Dysfunction 102

3. Validation of the International Society for Heart and Lung Transplantation Primary Graft Dysfunction Instrument in Heart Transplantation 104

4. Risk of Severe Primary Graft Dysfunction in Patients Bridged to Heart Transplantation with Continuous-flow Left Ventricular Assist Devices 105

5. Left Ventricular Assist Devices versus Medical Management in Ambulatory Heart Failure Patients: An Analysis of INTERMACS Profiles 4 and 5 to 7 from the ROADMAP Study 108

6. Risk of Stroke Early after Implantation of a Left Ventricular Assist Device 110

7. Outcomes of Venopulmonary Arterial Extracorporeal Life Support as Temporary Right Ventricular Support after Left Ventricular Assist Implantation 111

8. Venoarterial Extracorporeal Membrane Oxygenation for Postcardiotomy Shock: Risk Factors for Mortality 113

Index ***117***